声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。NMPA发布2025年11月14日药品批准证明文件送达信息,本批次共有129个受理号获批,其中:派格生物的维培那肽注射液获批上市,用于改善成人2型糖尿病患者的血糖控制。据公开资料显示,维培那肽注射液是派格生物自主研发的 1 类创新药物,这款药物是通过对...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。NMPA发布2025年11月14日药品批准证明文件送达信息,本批次共有129个受理号获批,其中:派格生物的维培那肽注射液获批上市,用于改善成人2型糖尿病患者的血糖控制。据公开资料显示,维培那肽注射液是派格生物自主研发的 1 类创新药物,这款药物是通过对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.